These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10769437)

  • 41. [Effects of long-term administration of alfacalcidol on bone mass and bone metabolism in patients with primary osteoporosis--comparison with calcium preparations].
    Nakatsuka K; Inaba M; Aratani H; Iba K; Sato T; Koike T; Miki T; Nishizawa Y; Morii H
    Nihon Ronen Igakkai Zasshi; 1997 Jul; 34(7):569-76. PubMed ID: 9388377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of further bone mass loss by nasal calcitonin in patients on long term glucocorticoid therapy for asthma: a two year follow up study.
    Luengo M; Pons F; Martinez de Osaba MJ; Picado C
    Thorax; 1994 Nov; 49(11):1099-102. PubMed ID: 7831624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects.
    Paz-Pacheco E; Fuleihan GE; LeBoff MS
    J Bone Miner Res; 1995 Nov; 10(11):1713-8. PubMed ID: 8592948
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy.
    Loddenkemper K; Bohl N; Perka C; Burmester GR; Buttgereit F
    Rheumatol Int; 2006 Feb; 26(4):331-6. PubMed ID: 15887044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.
    Richy F; Ethgen O; Bruyere O; Reginster JY
    Osteoporos Int; 2004 Apr; 15(4):301-10. PubMed ID: 14740153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.
    Ringe JD; Dorst A; Faber H; Ibach K; Preuss J
    Rheumatology (Oxford); 2003 Jun; 42(6):743-9. PubMed ID: 12730532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of DHEA supplementation on serum IGF-1, osteocalcin, and bone mineral density in postmenopausal, glucocorticoid-treated women.
    Papierska L; Rabijewski M; Kasperlik-Załuska A; Zgliczyński W
    Adv Med Sci; 2012 Jun; 57(1):51-7. PubMed ID: 22430044
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women.
    Pons F; Peris P; Guañabens N; Font J; Huguet M; Espinosa G; Ingelmo M; Muñoz-Gomez J; Setoain J
    Br J Rheumatol; 1995 Aug; 34(8):742-6. PubMed ID: 7551659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Mease PJ; Ginzler EM; Gluck OS; Schiff M; Goldman A; Greenwald M; Cohen S; Egan R; Quarles BJ; Schwartz KE
    J Rheumatol; 2005 Apr; 32(4):616-21. PubMed ID: 15801015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
    Geusens P; Dequeker J; Vanhoof J; Stalmans R; Boonen S; Joly J; Nijs J; Raus J
    Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis.
    Feldstein AC; Elmer PJ; Nichols GA; Herson M
    Osteoporos Int; 2005 Dec; 16(12):2168-74. PubMed ID: 16142501
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
    Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
    Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Influence of alphacalcidole on selected markers of the bone turnover in hemodialysed patients with secondary hyperparathyroidism].
    Nowak Z; Wierzbicki P; Konieczna M; Wańkowicz Z
    Pol Merkur Lekarski; 1998 Nov; 5(29):288-91. PubMed ID: 10101503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Etidronate prevents high dose glucocorticoid induced bone loss in premenopausal individuals with systemic autoimmune diseases.
    Nakayamada S; Okada Y; Saito K; Tanaka Y
    J Rheumatol; 2004 Jan; 31(1):163-6. PubMed ID: 14705236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Postmenopausal Canarian women receiving oral glucocorticoids have an increased prevalence of vertebral fractures and low values of bone mineral density measured by quantitative computer tomography and dual X-ray absorptiometry, without significant changes in parathyroid hormone.
    Sosa M; Jódar E; Saavedra P; Navarro MC; Gómez de Tejada MJ; Martín A; Peña P; Gómez J
    Eur J Intern Med; 2008 Jan; 19(1):51-6. PubMed ID: 18206602
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY; Lecart MP; Richy F
    J Rheumatol Suppl; 2005 Sep; 76():21-5. PubMed ID: 16142847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
    Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
    Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
    Ringe JD; Dorst A; Faber H; Ibach K; Sorenson F
    Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
    Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
    Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
    Reid DM; Adami S; Devogelaer JP; Chines AA
    Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.